Apollomics Enters $189 Million Deal for China Rights to Two GlycoMimetics Immunotherapies
January 06, 2020 at 08:34 AM EST
Apollomics of Hangzhou announced a $189 million agreement to develop two GlycoMimetics novel E-selectin-based immunotherapies in China for leukemia. Apollomics, which was incubated by OrbiMed Asia, will be responsible for developing uproleselan and GMI-1687 in mainland China, Hong Kong, Macau and Taiwan. GlycoMimetics will receive a $9 million upfront payment and be eligible for up to $180 million in milestones plus royalties. Apollomics is developing five assets: two novel mAbs that restore the body’s immune system along with three therapies that target growth signaling pathways. More details.... Stock Symbols: (NSDQ: GLYC) Share this with colleagues: // //